Gene Logic Sells GeneExpress Subscription to Japan s Takeda

NEW YORK, March 27 - Takeda has subscribed to Gene Logic's GeneExpress database and tools, Gene Logic said on Wednesday.

The multi-year deal gives the Japanese pharma the use of GeneExpress as well as broad access to Gene Logic's BioExpress and ToxExpress information and tools.

Financial terms of the deal, completed in collaboration with Amersham Biosciences KK, Gene Logic's sales and marketing partner in Japan, were not disclosed.

BioExpress includes genomic and clinical data derived from a variety of normal and diseased human tissues, tissues from model animal systems, and human and animal cell lines. ToxExpress is a database containing expression profiles from organs affected by toxicity and the results of rat and human cell samples treated with various compounds. Gene Logic claims ToxExpress can predict what compounds may cause liver toxicity. GeneExpress was designed to help researchers mine, analyze, index, and visualize data.

Takeda, a Japanese drug and vitamin powerhouse, has annual sales topping $7 billion.

Earlier in the month, Gene Logic sold a multi-year subscription to its GeneExpress and BioExpress data suites to Japanese pharma Daiichi.